NanoLogix Changes Stock Symbol From IFEC to NNLX to Reflect Name Change

May 10, 2005, 01:00 ET from NanoLogix, Inc.

    SHARON, Pa., May 10 /PRNewswire-FirstCall/ -- NanoLogix, Inc.,
 (Pink Sheets:   NNLX - News), formerly Infectech, Inc. (Pink Sheets:   IFEC), is a
 Nanobiotechnology company engaged in the research, development and
 commercialization of technologies for the production of bacteria and disease
 testing kits, alternative sources of fuel, cancer therapy and remediation of
 toxic materials.  The Company announced today that its stock symbol has
 changed from:  OTC: IFEC to OTC: NNLX in accordance with its name change to
     NanoLogix's portfolio of 31 patents have yielded a method vital to the
 development of nanotechnology products, a method for low cost hydrogen
 production, FDA registered products in the medical device industry, a genomic
 cancer therapy and methods for cleaning up toxic environments using
 bioremediation.  According to Lux Research, sales of products that incorporate
 nanotechnology are expected to explode over the next five years, from $12.98
 billion in 2004 to an estimated $507.74 billion in 2010. The following
 validates the value of NanoLogix's broad patent portfolio along with its
 current and future product lines.
     For a detailed report on NanoLogix please visit:
      Investment Highlights:
      - FDA Registration of Identikits.  NanoLogix receives medical device
        exemption from FDA and can begin manufacturing and selling its
        biophasic system devices which detect Mycobacterium Tuberculosis (TB),
        Mycobacterium avium complex (MAC), Paratuberculosis, Pseudomonas,
        Nocardia and up to 34 different bacteria.
      - The Indian Journal of Tuberculosis publishes Mahatma Gandhi Institute
        of Medical Sciences research for isolation of Mycobacterium Avium
        Complex (MAC) using NanoLogix patented paraffin baiting technology.
      - Results from initial hydrogen bioreactor study shows 50% hydrogen
      - Ohio State University validates NanoLogix patented paraffin baiting
      - NanoLogix signs deal with Gannon University to build hydrogen
      - NanoLogix in discussions with one of the largest juice companies in
        the U.S. to demonstrate feasibility of a pilot scale unit to convert
        millions of gallons of wastewater per year into hydrogen gas.
      - The Royal Society of Chemistry publishes University of Cincinnati
        research for developing Biochips using NanoLogix patented paraffin
        baiting technology.
      - National Science Foundation awards grant to University of Cincinnati
        for BioMEMS research using NanoLogix's patented paraffin baiting
      - NanoLogix granted patent for nontoxic genomics therapy for cancer.
      - Journal of Laboratory Technology for Bioresearch (BioTechniques)
        publishes NanoLogix's research on cell death using hydrophobic
     About NanoLogix, Inc.
     NanoLogix, Inc., , is a technology application
 innovator of biogas products and services designed to assist in worldwide
 energy independence and reduce pollution from renewable, environmentally-
 friendly energy sources. NanoLogix is also engaged in the research and
 development of diagnostic test kits designed to be used for the rapid
 identification of infectious human diseases. The Company's patents span the
 identification and antibiotic sensitivity testing of 34 disease-producing
 bacteria, including M. tuberculosis (TB), Mycobacterium avium-intracellulare
 (MAI), pseudomonas, and nocardia. These bacteria are cited as prominent causes
 of morbidity and mortality in patients with cancer, cystic fibrosis, and AIDS.
 Additionally, NanoLogix owns a patent for the nontoxic induction of apoptosis
 in cancer cells utilizing hydrophobic hydrocarbons. Apoptosis is a method for
 inducing a genetically based induction of "cell suicide" in cells. The
 Company's 31 patents can be viewed by visiting .
     This press release contains statements, which may constitute
 "forward-looking statements" within the meaning of the Securities Act of 1933
 and the Securities Exchange Act of 1934, as amended by the Private Securities
 Litigation Reform Act of 1995. Those statements include statements regarding
 the intent, belief or current expectations of NanoLogix, Inc., and members of
 its management as well as the assumptions on which such statements are based.
 Prospective investors are cautioned that any such forward-looking statements
 are not guarantees of future performance and involve risks and uncertainties,
 and that actual results may differ materially from those contemplated by such
 forward-looking statements. Important factors currently known to management
 that could cause actual results to differ materially from those in forward-
 statements include fluctuation of operating results, the ability to compete
 successfully and the ability to complete before-mentioned transactions. The
 company undertakes no obligation to update or revise forward-looking
 statements to reflect changed assumptions, the occurrence of unanticipated
 events or changes to future operating results.

SOURCE NanoLogix, Inc.